Back to search

Article

CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-TKI via suppressing PI3K/AKT

2020-05-26

Abstract excerpt

<title>Abstract</title> <p>Background : While anti-HER2 tyrosine kinase inhibitors (TKIs) have radically prolonged survival and improved prognosis in HER2-positive breast cancer patients, resistance to these therapies is a constant obstacle leading to TKIs treatment failure and tumor progression.Methods : To develop new strategies to enhance TKIs efficiency by combining synergistic gene targets, we performed pane...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
011d208d-a810-55cc-aa64-4ea7dc8bd383
DOI
10.21203/rs.3.rs-30034/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-TKI via suppressing PI3K/AKTDOI 10.21203/rs.3.rs-30034/v1
A comprehensive luminal breast cancer patient‐derived xenografts ( PDX ) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4 /6 inhibitorsSemantic proximity
Cooperative regulation of coupled oncoprotein synthesis and stability in triple-negative breast cancer by EGFR and CDK12/13Semantic proximity
Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.Semantic proximity
Impact of homologous recombination deficiency on CDK4/6 inhibitor sensitivity in HR+/HER2-breast cancerSemantic proximity
Breast cancer mutations HER2 <sup>V777L</sup> and PIK3CA <sup>H1047R</sup> activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistanceSemantic proximity
The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancerSemantic proximity
BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathwaysSemantic proximity
Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21-CDK4/6-Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance.Semantic proximity
Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors.Semantic proximity
Rational design of HER2-targeted combination therapies to reverse drug resistance in fibroblast-protected HER2+ breast cancer cellsSemantic proximity
Kinome focused CRISPR-Cas9 screens in African ancestry patient-derived breast cancer organoids identify essential kinases and synergy of EGFR and FGFR1 inhibitionSemantic proximity
CRISPR-mediated targeting of HER2 inhibits cell proliferation through a dominant negative mutation.Semantic proximity
Select a neighboring publication to make it the new centre.